Table 1 Relationship between TRIM21 expression and clinicopathological features of CRC patients.
From: TRIM21-mediated PRMT1 degradation attenuates colorectal cancer malignant progression
Variables | TRIM21 expression (n = 485) | ||
|---|---|---|---|
Low (%) | High (%) | P* | |
Age (years) | 0.455 | ||
≤56 | 86 (54.1) | 73 (45.9) | |
>56 | 188 (57.7) | 138 (42.3) | |
Gender | 0.284 | ||
Males | 149 (54.4) | 125 (45.6) | |
Females | 125 (59.2) | 86 (40.8) | |
Tumor diameter | < 0.001 | ||
<5 cm | 176 (49.7) | 178 (50.3) | |
≥5 cm | 98 (75.4) | 32 (24.6) | |
Differentiation | < 0.001 | ||
Poor | 72 (75.0) | 24 (25.0) | |
Moderate/high | 198 (51.6) | 186 (48.4) | |
Lymph node metastasis | < 0.001 | ||
Negative | 126 (45.7) | 150 (54.3) | |
Positive | 135 (68.9) | 61 (31.1) | |
Distant metastasis | < 0.001 | ||
M0 | 253 (54.5) | 211 (45.5) | |
M1 | 21 (100.0) | 0 (0.0) | |
TNM stage | < 0.001 | ||
I / II | 119 (44.2) | 150 (55.8) | |
III / IV | 155 (71.8) | 61 (28.2) | |
